Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Salivary Gland Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
7 drugs · 16 active trials
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Docetaxel | Phase 3 | Phase 3 | 4 | 1 | 1 | 7 | 0 | — | — | 2002-10 |
| Carboplatin | Phase 3 | Phase 3 | 3 | 0 | 1 | 9 | 0 | — | — | 2006-12 |
| Gemcitabine | Phase 3 | Phase 3 | 3 | 1 | 1 | 9 | 0 | — | — | Mar 31, 2009 |
| Cisplatin | Phase 3 | Phase 3 | 3 | 0 | 2 | 6 | 0 | — | — | 2006-12 |
| Fluorouracil | Phase 3 | Phase 3 | 1 | 0 | 1 | 9 | 0 | — | — | 2001-07 |
| Bevacizumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 6 | 0 | — | — | 2001-07 |
| Nab-paclitaxel | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | Mar 26, 2013 |
| Pembrolizumab | Phase 2 | Phase 2 | 8 | 0 | 0 | 11 | 0 | — | — | Oct 8, 2015 |
| Lenvatinib | Phase 2 | Phase 2 | 4 | 1 | 0 | 4 | 0 | — | — | May 19, 2016 |
| Nivolumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 7 | 0 | — | — | Jan 30, 2017 |
| Goserelin | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | May 30, 2019 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Aug 15, 2023 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jul 27, 2023 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Dec 24, 2020 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 1 | 0 | 0 | 9 | 0 | — | — | 2001-12 |
| Irinotecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | 2001-12 |
| Ipilimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Jan 30, 2017 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-07 |
| Darolutamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 17, 2020 |
| Olaparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jun 22, 2021 |
| Abemaciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 1, 2023 |
| Amivantamab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 5, 2022 |
| Bicalutamide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 27, 2022 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 19, 2015 |
| Epirubicin | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 20, 2026 |
| Leuprolide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2023 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2021 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 27, 2017 |
| Zanidatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 14, 2025 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2005-01 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | Mar 26, 2012 |
| Leucovorin | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Mar 26, 2012 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-07 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-09 |
| Paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2002-03 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-10 |
| Dasatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-07 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-11 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Aug 6, 2010 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 23, 2012 |
| Axitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-12 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-06 |
| Capecitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-10 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-03 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-08 |
| Metformin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 21, 2013 |
| Selinexor | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-06 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 22, 2019 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-05 |
| Cabozantinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 5, 2018 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.